Post-operative pain control in patients who have received the breast enhanced recovery after surgery protocol

Kristina Dzeba MD, Jacob Lammers DO, Joseph Gabra D.Eng, Andrew Fenton MD, Mary Murray MD, & Amanda Mendiola MD

Introduction

Increasingly, many different surgical subspecialties have adopted enhanced recovery after surgery (ERAS) programs to facilitate improved patient experiences. Using fewer narcotics while employing other pain modalities to reduce patients' pain is critical in the setting of the United States' current opioid crisis.

Based on data from the CDC:

- 128 people die every day in the US from opioid overdose totaling 46,802 Americans in 2018 [1,4]
- 1.7 million Americans engage in substance abuse of opioids [2]
- Financial losses of opioid abuse are about $78.5 billion per year [3]

In 2015, the Enhanced Recovery after Surgery Society established a set of consensus guidelines for breast surgical oncology:

1. Preoperative: patient education, scopolamine patches, and administration of non-opioid analgesics
2. Intraoperative: euvolemia, minimal narcotic usage, antiemetics, regional anesthesia, normothermia, and VTE prophylaxis

Numerous publications demonstrated the utility of ERAS applications involving various types of breast surgery, including flap reconstruction, implant-based reconstruction, and lumpectomies [6,7,8,9,10,11].

Objectives

This study's primary goal is to evaluate post-operative pain control with the implementation of the BERAS protocol. We hypothesized that it would improve post-operative pain control.

Methods

Retrospective chart review of patients who underwent breast surgery from January 1, 2016 to June 30, 2019

- Implemented B-ERAS protocol in February 2017
- Excluded patients who underwent breast surgery during February 2017
- Compared between patients in the B-ERAS group and the pre-B-ERAS group
- Performed Mann Whitney U and Chi-squared tests

Results

- BERAS group had significantly lower self-reported PACU pain scale than Pre-BERAS group (p=0.0213, Figure 1)
- BERAS group had significantly lower opioid consumption in all settings, as measured in oral MMEs (p<0.0001, Figure 2)


definitions

Table 1: Pre-BERAS and BERAS Group Comparisons

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-BERAS (n = 196)</th>
<th>BERAS (n = 418)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>62.0 (52.0-69.8)</td>
<td>62.0 (53.0-69.0)</td>
<td>0.5942</td>
</tr>
<tr>
<td>BMI</td>
<td>28.9 (23.9-33.6)</td>
<td>29.3 (25.0-34.1)</td>
<td>0.1746</td>
</tr>
<tr>
<td>Length of Stay (hrs)</td>
<td>3.5 (2.2-19.5)</td>
<td>3.0 (2.2-17.5)</td>
<td>0.1742</td>
</tr>
<tr>
<td>Caucasian</td>
<td>183 (93.4)</td>
<td>355 (84.9)</td>
<td>0.0097</td>
</tr>
<tr>
<td>Malignancy</td>
<td>180 (91.8)</td>
<td>396 (96.2)</td>
<td>0.0997</td>
</tr>
<tr>
<td>Unilateral</td>
<td>136 (69.4)</td>
<td>339 (82.5)</td>
<td>0.0003</td>
</tr>
<tr>
<td>Diabetes</td>
<td>25 (13.1)</td>
<td>74 (18.1)</td>
<td>0.124</td>
</tr>
<tr>
<td>Depression</td>
<td>52 (26.7)</td>
<td>102 (24.5)</td>
<td>0.5688</td>
</tr>
<tr>
<td>Anxiety</td>
<td>63 (32.1)</td>
<td>83 (20.0)</td>
<td>0.001</td>
</tr>
<tr>
<td>Taking Antidepressant</td>
<td>6 (4.2)</td>
<td>23 (6.3)</td>
<td>0.3661</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>58 (29.7)</td>
<td>96 (23.1)</td>
<td>0.0796</td>
</tr>
<tr>
<td>Taking Narcotics Pre-Op</td>
<td>26 (13.3)</td>
<td>17 (4.1)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>7 (2.6)</td>
<td>10 (2.4)</td>
<td>0.4147</td>
</tr>
<tr>
<td>Chronic Pain</td>
<td>64 (32.7)</td>
<td>56 (13.5)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Tobacco Use</td>
<td>26 (13.3)</td>
<td>36 (8.6)</td>
<td>0.0761</td>
</tr>
<tr>
<td>Neo-Adjuvant Therapy</td>
<td>39 (20.4)</td>
<td>63 (15.3)</td>
<td>0.1182</td>
</tr>
</tbody>
</table>

Notes: Continuous Data presented as median (Q1-Q3); Categorical data presented as n (%); Missing data excluded from analyses on a test-by-test basis

Discussion

Our results demonstrate that implementation of a breast-specific enhanced recovery after surgery protocol can:

- Improve the patient's pain experience
- Decrease the patient's narcotic consumption

Notably, our findings still achieved significance with lower opioid consumption in the BERAS group after the exclusion of patients with chronic pain and pre-operative narcotic use.

References


Acknowledgements

The authors wish to thank the Department of Surgery of the Cleveland Clinic Akron General and the Department of Anesthesia of the Cleveland Clinic Akron General for their support of this research.

For further information, please contact Dr. Kristina Dzeba at dzebak@ccf.org or at the Akron General Reflections Breast Center, One Akron General Avenue, Akron, OH 44307.